Jane Sorensen - Neurocrine Biosciences Head Relations
| N1BI34 Stock | 35.67 0.00 0.00% |
Executive
Jane Sorensen is Head Relations of Neurocrine Biosciences
| Phone | 858 617 7600 |
| Web | https://www.neurocrine.com |
Neurocrine Biosciences Management Efficiency
The company has return on total asset (ROA) of 0.0701 % which means that it generated a profit of $0.0701 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1003 %, meaning that it generated $0.1003 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Carla Silva | Lloyds Banking Group | 49 | |
| Arthur Smith | Credit Acceptance | 50 | |
| Jonathan Lum | Credit Acceptance | 46 | |
| David Gledhill | Lloyds Banking Group | 61 | |
| Erin Kerber | Credit Acceptance | 44 | |
| David Oldfield | Lloyds Banking Group | N/A | |
| Letitia Smith | Lloyds Banking Group | 57 | |
| Eduardo Cunha | Lloyds Banking Group | 60 | |
| Noah Kotch | Credit Acceptance | 53 | |
| Douglas Busk | Credit Acceptance | 63 | |
| Matt Smith | Lloyds Banking Group | N/A | |
| Ravi Mohan | Credit Acceptance | N/A | |
| Andrew Rostami | Credit Acceptance | N/A | |
| Daniel Ulatowski | Credit Acceptance | 51 | |
| Catherine Cheetham | Lloyds Banking Group | 60 | |
| John Chambers | Lloyds Banking Group | N/A | |
Management Performance
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0701 |
Neurocrine Biosciences Leadership Team
Elected by the shareholders, the Neurocrine Biosciences' board of directors comprises two types of representatives: Neurocrine Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurocrine. The board's role is to monitor Neurocrine Biosciences' management team and ensure that shareholders' interests are well served. Neurocrine Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurocrine Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Cooke, Chief Officer | ||
| Matthew Abernethy, Chief Officer | ||
| Jane Sorensen, Head Relations | ||
| Eiry MD, Chief Officer | ||
| Eric Benevich, Chief Officer | ||
| Darin Lippoldt, Chief Sec | ||
| Jude Onyia, Chief Officer | ||
| Kevin Gorman, CEO Director | ||
| Dimitri Grigoriadis, Chief Officer | ||
| Kyle Gano, Chief Officer |
Neurocrine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurocrine Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0701 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 58.19 B | |||
| Shares Outstanding | 1.93 B | |||
| Price To Book | 7.33 X | |||
| Price To Sales | 44.39 X | |||
| Revenue | 1.13 B | |||
| Gross Profit | 1 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Neurocrine Stock
When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Neurocrine Stock refer to our How to Trade Neurocrine Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.